CG Oncology, Inc. (CGON)
NASDAQ: CGON · Real-Time Price · USD
25.46
-0.40 (-1.55%)
Jun 16, 2025, 4:00 PM - Market closed
CG Oncology Stock Forecast
Stock Price Forecast
The 10 analysts that cover CG Oncology stock have a consensus rating of "Strong Buy" and an average price target of $64, which forecasts a 151.37% increase in the stock price over the next year. The lowest target is $41 and the highest is $75.
Price Target: $64 (+151.37%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CG Oncology stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 7 | 6 | 6 |
| Buy | 3 | 3 | 3 | 3 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 10 | 10 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Buy Maintains $55 → $52 | Buy | Maintains | $55 → $52 | +104.24% | May 19, 2025 |
| JP Morgan | JP Morgan | Buy Initiates $41 | Buy | Initiates | $41 | +61.04% | May 2, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $66 → $68 | Buy | Maintains | $66 → $68 | +167.09% | Apr 29, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $75 | Buy | Reiterates | $75 | +194.58% | Apr 28, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $75 | Strong Buy | Reiterates | $75 | +194.58% | Apr 28, 2025 |
Financial Forecast
Revenue This Year
772.28K
from 1.14M
Decreased by -32.20%
Revenue Next Year
114.45M
from 772.28K
Increased by 14,719.70%
EPS This Year
-1.84
from -1.41
EPS Next Year
-1.71
from -1.84
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 2.1M | 268.6M | 347.8M | ||
| Avg | 772,283 | 114.5M | 236.1M | ||
| Low | n/a | 19.6M | 130.3M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 84.4% | 34,673.5% | 203.9% | ||
| Avg | -32.2% | 14,719.7% | 106.3% | ||
| Low | - | 2,437.9% | 13.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.05 | -0.11 | 0.87 | ||
| Avg | -1.84 | -1.71 | -0.40 | ||
| Low | -2.16 | -3.49 | -1.72 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.